BioNTech Good Will from 2010 to 2024
| BNTX Stock | USD 92.28 0.44 0.47% |
Good Will | First Reported 2010-12-31 | Previous Quarter 362.5 M | Current Value 380.6 M | Quarterly Volatility 128 M |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0113 or PTB Ratio of 1.19. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Good Will |
Latest BioNTech's Good Will Growth Pattern
Below is the plot of the Good Will of BioNTech SE over the last few years. It is an intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors. BioNTech's Good Will historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
| Good Will | 10 Years Trend |
|
Good Will |
| Timeline |
BioNTech Good Will Regression Statistics
| Arithmetic Mean | 61,573,733 | |
| Geometric Mean | 3,653,272 | |
| Coefficient Of Variation | 207.89 | |
| Mean Deviation | 82,663,671 | |
| Median | 534,000 | |
| Standard Deviation | 128,004,702 | |
| Sample Variance | 16385.2T | |
| Range | 380.1M | |
| R-Value | 0.69 | |
| Mean Square Error | 9246.7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 19,747,157 | |
| Total Sum of Squares | 229392.9T |
BioNTech Good Will History
About BioNTech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include BioNTech income statement, its balance sheet, and the statement of cash flows. BioNTech investors use historical funamental indicators, such as BioNTech's Good Will, to determine how well the company is positioned to perform in the future. Although BioNTech investors may use each financial statement separately, they are all related. The changes in BioNTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioNTech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Good Will | 362.5 M | 380.6 M |
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
| 0.7 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.84 | PFE | Pfizer Inc Aggressive Push | PairCorr |
Moving against BioNTech Stock
| 0.53 | SERA | Sera Prognostics | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of BioNTech Correlation against competitors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 0.51 | Revenue Per Share 11.369 | Quarterly Revenue Growth (0.85) | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.